BEARINGPOINT
3.3.2020 09:02:13 CET | Business Wire | Press release
Management and technology consultancy BearingPoint announced today that full-year 2019 revenues hit a record €780 million, a 6% increase from the previous year, due in particular to new revenue streams and innovative business services. The firm delivered projects for clients in over 70 countries. Bookings for 2019 came in at €949 million, which was up 15% compared to the prior year. The substantial growth in bookings points to a strong 2020. BearingPoint said its Strategy 2025, launched last year, has created a solid foundation for sustainable growth. To support growth, BearingPoint hired 1,400 people last year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005041/en/
“In 2019, we laid the foundation for the future of our firm by developing our Strategy 2025. Three major ambitions drive this strategy. One, we put people in the center. Two, we’re going to outperform the market every year. Three, we’re going to be within the top three players in selected areas we decide to play,” said Managing Partner Kiumars Hamidian. “Despite difficult market conditions in certain segments and market geographies, our firm proved to be resilient and able to grow. 2020 is all about the execution of our strategy. Our backlog is strong, the market conditions in most of our countries are promising, and team spirit is extremely high.”
Strategic growth and innovation
BearingPoint established Business Services as a separate unit at the beginning of 2019. Business Services provides IP-driven digital assets and managed services beyond SaaS. The firm also accelerated the growth of its software business by further verticalizing its two product lines: BearingPoint Beyond and BearingPoint RegTech. BearingPoint Beyond is a digital platform solution provider that helps organizations reinvent their business model and grow revenue by utilizing digital platforms and partner ecosystems. BearingPoint RegTech is a leading provider of innovative regulatory and risk technology solutions and launched an international “regulatory reporting factory” last year.
To support its overall growth objectives, BearingPoint also made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. With the acquisition, BearingPoint continued its growth strategy in selected markets with consultancies that are highly focused and strongly differentiated.
Once again, there was a strong focus on creating innovation. More than 130 ideas, startups, and initiatives were submitted to the firm’s “Hub of Innovation,” and over 20 minimum viable products (MVPs) were developed. Market observers again singled out BearingPoint in 2019 for its innovation and strengths, with 90 analyst recognitions and various awards.
Putting people in the center
As part of putting people at the center, one of the three core ambitions of its Strategy 2025, BearingPoint established a long-term incentive plan that rewards employee loyalty. The firm also established LGBTQ+ and All Inclusive communities and expanded its (Y)Our Ways program. BearingPoint’s (Y)Our Ways is about redesigning the way people work to achieve tangible business outcomes. It leverages IP, talent, and expertise. People-centric by design, (Y)Our Ways is transforming the way BearingPoint makes a difference for its people, clients, and ecosystems.
10 years of BearingPoint – 10 years of success
In 2019, BearingPoint celebrated 10 years of success as an independent, Partner-led management and technology consultancy by giving back to people, planet, and society in the biggest CSR campaign in the firm’s history. The #10DaysOfCaring campaign saw BearingPoint’s people across its offices worldwide participate in more than 150 different activities ranging from planting trees and cycling to work to donating blood and volunteering for local nonprofits. BearingPoint said that #10DaysOfCaring underlined the firm’s culture of teamwork, creativity, and a can-do attitude.
BearingPoint used the momentum from the campaign to start new initiatives, like launching new affinity networks. The firm also signed the UN Global Compact in 2019 and committed itself to the 10 underlying principles that include environmental and climate protection. One way BearingPoint showed its commitment was by making its business travel activities climate-neutral for all its business units globally.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
